GNI Group

2160.TSE

21.63 USD

-0.24

-1.10%

Overview

Last close

21.63 usd

Market cap

1.08B usd

52 week high

25.28 usd

52 week low

8.42 usd

Target price

25.58 usd

Valuation

P/E

22.4039

Forward P/E

N/A

Price/Sales

6.9882

Price/Book Value

4.4862

Enterprise Value

996.84M usd

EV/Revenue

6.6221

EV/EBITDA

14.4829

Key financials

Revenue TTM

157.12M usd

Gross Profit TTM

97.97M usd

EBITDA TTM

10.26M usd

Earnings per Share

0.91 usd

Dividend

N/A usd

Total assets

429.09M usd

Net debt

-63.97M usd

About

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573 that is in phase II for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.